The drug will be studied through a population-level agreement.
Inclisiran, a bi-annual injection to lower cholesterol, is set to be studied in UK patients as part of a large-scale NHS clinical trial expected to start later this year.
In a world-first, the drug is expected to be available through a population-level agreement – pioneering a game-changing approach to reducing the risk of heart disease.
According to the Department of Health and Social Care (DHSC), early clinical trial results suggest that if inclisiran is given to 300,000 patients annually, it could help prevent 55,000 heart attacks and strokes, and has the potential of saving 30,000 lives in the next 10 years.
Heart disease is the world’s biggest killer and the second biggest cause of death in the UK and 2 and a half million patients currently relying on statins to lower their cholesterol.
Recent trials have shown inclisiran can halve bad cholesterol in just 2 weeks.
A huge stride forward.
Health and Social Care Secretary Matt Hancock said: “As Health Secretary, I’m determined find ways to save as many lives as possible, and to do my best to stop terrible conditions like heart disease from taking people from their family and friends far too soon.
“This partnership is fantastic news and is a huge stride forwards in helping to achieve this. This collaboration has the potential to save 30,000 lives over the next 10 years and is proof that the UK continues to be the world-leading destination for revolutionary healthcare.”
Professor of Medicine and Epidemiology at the University of Oxford Martin Landray said: “This trial provides an opportunity to demonstrate how a highly streamlined trial can be conducted within the UK by combining elements of patients already diagnosed cardiovascular disease and received treatment through the successful ORION-4 trial with the high-throughput clinics developed for UK Biobank.
“The trial will provide both a very reliable test of the efficacy and safety of inclisiran to support a population-health approach to the management of cholesterol, and act as an exemplar for future trials of other treatments in the UK.